These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 27451002)

  • 1. Short-term isocaloric fructose restriction lowers apoC-III levels and yields less atherogenic lipoprotein profiles in children with obesity and metabolic syndrome.
    Gugliucci A; Lustig RH; Caccavello R; Erkin-Cakmak A; Noworolski SM; Tai VW; Wen MJ; Mulligan K; Schwarz JM
    Atherosclerosis; 2016 Oct; 253():171-177. PubMed ID: 27451002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [THE LIPOLYSIS IN PHYLOGENETICALLY EARLY LIPOPROTEINS OF LOW DENSITY AND MORE LATER LIPOPROTEINS OF VERY LOW DENSITY: FUNCTION AND DIAGNOSTIC VALUE OF APOE AND APOC-III].
    Rozhkova TA; Titov VN; Amelyushkina VA; Kaba SI; Kukhartchuk VV
    Klin Lab Diagn; 2015 Dec; 60(12):4-14. PubMed ID: 27032246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isocaloric fructose restriction and metabolic improvement in children with obesity and metabolic syndrome.
    Lustig RH; Mulligan K; Noworolski SM; Tai VW; Wen MJ; Erkin-Cakmak A; Gugliucci A; Schwarz JM
    Obesity (Silver Spring); 2016 Feb; 24(2):453-60. PubMed ID: 26499447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dietary carbohydrate and fat on plasma lipoproteins and apolipoproteins C-II and C-III in healthy men.
    Kashyap ML; Barnhart RL; Srivastava LS; Perisutti G; Vink P; Allen C; Hogg E; Brady D; Glueck CJ; Jackson RL
    J Lipid Res; 1982 Aug; 23(6):877-86. PubMed ID: 7130856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enrichment of Triglyceride-Rich Lipoproteins with Apolipoprotein C-I Is Positively Associated with Their Delayed Plasma Clearance Independently of Other Transferable Apolipoproteins in Postmenopausal Overweight and Obese Women.
    Wassef H; Bissonnette S; Dufour R; Davignon J; Faraj M
    J Nutr; 2017 May; 147(5):754-762. PubMed ID: 28356429
    [No Abstract]   [Full Text] [Related]  

  • 7. Lipid and apolipoprotein levels and distribution in patients with hypertriglyceridemia: effect of triglyceride reductions with atorvastatin.
    Le NA; Innis-Whitehouse W; Li X; Bakker-Arkema R; Black D; Brown WV
    Metabolism; 2000 Feb; 49(2):167-77. PubMed ID: 10690940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism.
    Chan DC; Nguyen MN; Watts GF; Barrett PH
    J Clin Endocrinol Metab; 2008 Feb; 93(2):557-64. PubMed ID: 18000086
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apolipoprotein C-III and its defined lipoprotein subspecies in relation to incident diabetes: the Multi-Ethnic Study of Atherosclerosis.
    Aroner SA; Furtado JD; Sacks FM; Tsai MY; Mukamal KJ; McClelland RL; Jensen MK
    Diabetologia; 2019 Jun; 62(6):981-992. PubMed ID: 30949716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.
    Zheng C; Khoo C; Furtado J; Sacks FM
    Circulation; 2010 Apr; 121(15):1722-34. PubMed ID: 20368524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein E in VLDL and LDL with apolipoprotein C-III is associated with a lower risk of coronary heart disease.
    Mendivil CO; Rimm EB; Furtado J; Sacks FM
    J Am Heart Assoc; 2013 May; 2(3):e000130. PubMed ID: 23672999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose-dependent effect of rosuvastatin on VLDL-apolipoprotein C-III kinetics in the metabolic syndrome.
    Ooi EM; Watts GF; Chan DC; Chen MM; Nestel PJ; Sviridov D; Barrett PH
    Diabetes Care; 2008 Aug; 31(8):1656-61. PubMed ID: 18509206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apolipoprotein C-III, a strong discriminant of coronary risk in men and a determinant of the metabolic syndrome in both genders.
    Onat A; Hergenç G; Sansoy V; Fobker M; Ceyhan K; Toprak S; Assmann G
    Atherosclerosis; 2003 May; 168(1):81-9. PubMed ID: 12732390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.
    Furtado JD; Campos H; Sumner AE; Appel LJ; Carey VJ; Sacks FM
    Am J Clin Nutr; 2010 Oct; 92(4):714-22. PubMed ID: 20826623
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of nicotinic acid therapy on plasma lipoproteins and very low density lipoprotein apoprotein C subspecies in hyperlipoproteinemia.
    Yovos JG; Patel ST; Falko JM; Newman HA; Hill DS
    J Clin Endocrinol Metab; 1982 Jun; 54(6):1210-5. PubMed ID: 7076797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Correlation analysis of lipids and apolipoproteins in plasma HDL, LDL and VLDL of normal subjects and endogenous hypertriglyceridemics].
    Fan P; Liu B
    Hua Xi Yi Ke Da Xue Xue Bao; 1995 Jun; 26(2):141-5. PubMed ID: 7490018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma lipoprotein distribution of apoC-III in normolipidemic and hypertriglyceridemic subjects: comparison of the apoC-III to apoE ratio in different lipoprotein fractions.
    Fredenrich A; Giroux LM; Tremblay M; Krimbou L; Davignon J; Cohn JS
    J Lipid Res; 1997 Jul; 38(7):1421-32. PubMed ID: 9254067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Independent regulation of plasma apolipoprotein C-II and C-III concentrations in very low density and high density lipoproteins: implications for the regulation of the catabolism of these lipoproteins.
    Le NA; Gibson JC; Ginsberg HN
    J Lipid Res; 1988 May; 29(5):669-77. PubMed ID: 3411241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.
    Chan DC; Watts GF; Ooi EM; Ji J; Johnson AG; Barrett PH
    Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1831-7. PubMed ID: 18566295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.